Lexeo Therapeutics Inc
LXEO4.770USD
+0.160+3.47%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
158.33MValor de mercado
PerdaP/L TTM
Mais detalhes de Lexeo Therapeutics Inc Empresa
Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimers disease are treated. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).
Informações da empresa
Código da empresaLXEO
Nome da EmpresaLexeo Therapeutics Inc
Data de listagemNov 03, 2023
CEOMr. R. Nolan Townsend
Número de funcionários72
Tipo de títulosOrdinary Share
Fim do ano fiscalNov 03
Endereço345 Park Avenue South
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal10010
Telefone12125479879
Sitehttps://www.lexeotx.com/
Código da empresaLXEO
Data de listagemNov 03, 2023
CEOMr. R. Nolan Townsend
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kyle Rasbach
Dr. Kyle Rasbach
Chief Financial Officer
Chief Financial Officer
40.88K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
5.46K
-9.69%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Paula H. J. Cholmondeley
Ms. Paula H. J. Cholmondeley
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jenny R. Robertson, J.D.
Ms. Jenny R. Robertson, J.D.
Chief Legal Officer
Chief Legal Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Kyle Rasbach
Dr. Kyle Rasbach
Chief Financial Officer
Chief Financial Officer
40.88K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
5.46K
-9.69%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Detalhamento da receita
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
0.00
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
13.73%
Frazier Life Sciences Management, L.P.
13.33%
Affinity Asset Advisors LLC
10.20%
Longitude Capital Management Co., LLC
8.33%
Citadel Advisors LLC
8.20%
Other
46.21%
Investidores
Investidores
Proporção
Janus Henderson Investors
13.73%
Frazier Life Sciences Management, L.P.
13.33%
Affinity Asset Advisors LLC
10.20%
Longitude Capital Management Co., LLC
8.33%
Citadel Advisors LLC
8.20%
Other
46.21%
Tipos de investidores
Investidores
Proporção
Hedge Fund
41.71%
Investment Advisor/Hedge Fund
26.11%
Investment Advisor
16.31%
Venture Capital
16.20%
Private Equity
13.81%
Research Firm
7.22%
Individual Investor
0.87%
Bank and Trust
0.08%
Pension Fund
0.02%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
180
40.62M
122.36%
+311.25K
2025Q1
174
34.46M
103.80%
-3.48M
2024Q4
155
35.40M
107.08%
+416.99K
2024Q3
127
33.64M
101.76%
+2.87M
2024Q2
112
31.41M
96.45%
+1.88M
2024Q1
92
30.30M
97.67%
+5.87M
2023Q4
45
23.22M
87.68%
+3.57M
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
4.56M
13.73%
+218.67K
+5.04%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
4.42M
13.33%
+3.47M
+363.07%
May 28, 2025
Affinity Asset Advisors LLC
3.38M
10.2%
+1.90M
+128.56%
May 28, 2025
Longitude Capital Management Co., LLC
2.77M
8.33%
--
--
Sep 30, 2024
Citadel Advisors LLC
2.72M
8.2%
--
--
Mar 31, 2025
Mizuho Securities USA, LLC.
2.20M
6.64%
+276.70K
+14.36%
Mar 31, 2025
Millennium Management LLC
1.93M
5.82%
+861.89K
+80.44%
Apr 22, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
5.17%
+48.42K
+2.90%
Mar 31, 2025
Omega Fund Management, LLC
1.18M
3.57%
--
--
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
1.16M
3.49%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
iShares Micro-Cap ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
ProShares UltraPro Russell2000
0%
Proshares Ultra Russell 2000
0%
iShares Health Innovation Active ETF
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Growth ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.02%
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
iShares Russell 2000 Value ETF
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0%
Proshares Ultra Russell 2000
Proporção0%
iShares Health Innovation Active ETF
Proporção0%
iShares Russell 2000 ETF
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
